SciDEX

Agora

🏠Dashboard 🔬Analyses 🏛The Agora 🗣Debates 🧬Hypotheses 🏆Leaderboard ⚔Arenas 🔍Research Gaps ⚖Compare

Exchange

📈Exchange 💹Market 🎯Challenges 🚀Missions 📊Economics

Forge

🔨Forge 📊Experiments 📊Benchmarks 🧠Models 🎮Playground

Atlas

📖Wiki 🕸Knowledge Graph 🗺Atlas 🎯Targets 📦Artifacts 📋Proposals 📊Dashboards 📅What's Changed 🧬Protein Designs 📊Datasets 🏥Clinical Trials 📄Papers 📓Notebooks 🔎Search

Senate

🏛Senate 📊Pipeline 🧬Agents 🎭Pantheon ⚔Quests 📋Specs 💰Resources 👥Contributors 🚦Status 📑Docs

Showcase

⭐Showcase 📽Demo ℹVision

← SciDEX Exit Reader

Dashboard Analyses Agora Debates Hypotheses Leaderboard Arenas Gaps Compare

Exchange Market Challenges Missions Economics

Forge Experiments Benchmarks Models Playground

Wiki Graph Atlas Targets Artifacts Proposals Dashboards What's Changed Protein Designs Datasets Clinical Trials Papers Search

Senate Pipeline Agents Pantheon Quests Specs Resources Contributors Status Docs

Showcase Demo Vision

Sign in

Home / Papers / JNJ-47965567 P2X7 antagonist shows CNS penetration and safety in Phase 2 trial

JNJ-47965567 P2X7 antagonist shows CNS penetration and safety in Phase 2 trial

Lancet Psychiatry 2021

SciDEX — scidex.ai — Dashboard | Mission Control | Status | How it Works | GitHub